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Lipid droplets (LDs) are cellular organelles that are im-
portant for energy and lipid metabolism (1, 2). LD accu-
mulation is a hallmark of obesity and is linked to the 
metabolic syndrome and type II diabetes. LD accumulation 
is central to atherosclerosis development, in which macro-
phages in arterial walls accumulate cholesterol esters (CEs) 
in LDs to become foam cells. Finally, LDs accumulate in 
many carcinomas (3), and LDs and lipid metabolism are 
connected to renal clear cell carcinoma and prostate can-
cer (4–8).
Abstract Variations in the gene LDAH (C2ORF43), which 
encodes lipid droplet-associated hydrolase (LDAH), are among 
few loci associated with human prostate cancer. Homologs 
of LDAH have been identified as proteins of lipid droplets 
(LDs). LDs are cellular organelles that store neutral lipids, 
such as triacylglycerols and sterol esters, as precursors for 
membrane components and as reservoirs of metabolic en-
ergy. LDAH is reported to hydrolyze cholesterol esters and 
to be important in macrophage cholesterol ester metabo-
lism. Here, we confirm that LDAH is localized to LDs in sev-
eral model systems. We generated a murine model in which 
Ldah is disrupted but found no evidence for a major func-
tion of LDAH in cholesterol ester or triacylglycerol metabo-
lism in vivo, nor a role in energy or glucose metabolism.  
Our data suggest that LDAH is not a major cholesterol ester 
hydrolase, and an alternative metabolic function may be re-
sponsible for its possible effect on development of prostate 
cancer.—Kory, N., S. Grond, S. S. Kamet, Z. Li, N. Krahmer, 
C. Chitraju, P. Zhou, F. Fröhlich, I. Semova, C. Ejsing, 
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LDAH knockout mouse model 227
into HeLa cells or GFP-Sec61 for S2 cells. For localization studies 
in mammalian cells we generated expression plasmids containing 
human full-length LDAH with N-terminal mCherry- or GFP-tag 
under the CMV promoter. For LD-targeting studies, we expressed 
Drosophila full-length CG9186 with C-terminal mCherry-tag, the 
LD domain alone (amino acids (aa) 152–201 of Drosophila CG9186 
(CG9186aa152-201)), or Drosophila CG9186 with aa157–200 re-
placed by a AAAGGGGSGGGGS-linker ( aa157–200) under the 
actin promoter.
Fluorescence microscopy and image analysis
Immunofluorescence and spinning-disk confocal microscopy 
(100 × 1.4 NA oil immersion objective [Olympus], iMIC [Till], 
CSU22 [Yokugawa], iXonEM 897 [Andor]) were as described 
(33). LD area per cell was quantified as described (35).
Mouse experiments
All animal studies followed guidelines issued by Yale and Har-
vard universities’ institutional animal care and use committees. 
Mice were housed at 12-h light/12-h dark cycle with ad libitum 
access to food and water unless indicated otherwise.
The mouse strain used for this research project was created 
from embryonic stem cell clone 14003A-H3 (C57BL/6Ntac back-
ground, injected into B6(Cg)-Tyrc-2J/J blastocysts), obtained 
from the Knockout Mouse Project Repository (www.komp.org) 
and generated by Regeneron Pharmaceuticals. Forward primers 
S30636 (wild-type; 5′- CATCTCACCTCCTCTCCGTC-3′) or NeoF 
(knockout; 5′- TCATTCTCAGTATTGTTTTGCC-3′) and reverse 
primer SD (5′-CAGAGTCCTTCCCATGTCAC-3′) were used for 
genotyping.
Velocigene targeted alleles were created as described (36). 
Mice with germ-line transmission of the knockout allele were 
backcrossed from a C57BL/6Ntac onto a C57BL/6J background 
for a minimum of three generations. Mice were, therefore, a mix-
ture of these C57BL/6 strains. All animals were generated through 
breeding heterozygous animals.
Major determinants of whole-body energy balance were eval-
uated by the Yale School of Medicine Mouse Metabolic Pheno-
typing Center using the Comprehensive Lab Animal Monitoring 
System with Oxymax (Columbus Labs), including VO2, VCO2, 
activity, feeding, and drinking behavior. Body composition 
was determined by proton-NMR with the Bruker Minispec. 
Glucose homeostasis was evaluated by glucose tolerance test, 
according to recommendations of the NIH-funded Mouse Meta-
bolic Phenotyping Consortium (37). Briefly, mice were fasted 
overnight before we collected a basal plasma sample for glu-
cose and insulin measure. Mice were dosed intraperitoneally 
with 1 mg/g dextrose, and plasma was collected at set intervals 
for glucose and insulin measures. Glucose was measured by the 
glucose oxidase method using YSI, and insulin measured by 
radioimmunoassay.
Histology slides were prepared by the Yale School of Medicine 
Research Histology core or the Harvard Medical School Rodent 
Histology core.
For the cold-exposure experiments, animals were fasted over-
night and placed at 4°C for indicated times. Temperatures were 
determined using a rectal thermometer. Blood glucose was mea-
sured as described below. A 60% high-fat diet (D12492) was ob-
tained from Research Diets (New Brunswick, NJ).
Thin-layer chromatography
Lipids were extracted from tissue lysates (38), separated on sil-
ica TLC plates (Merck, Kenilworth, NJ) with n-heptane/isopropyl 
ether/acetic acid (60/40/4), and detected by cerium molybdate 
staining. Bands were identified by comparing with standards.
Among genes that encode LD proteins, LDAH is associ-
ated with prostate cancer. The SNP rs13385191 in intron 6 
of LDAH is associated with increased prostate cancer risk 
(9–12). A rare A>G variant is associated with a difference in 
LDAH mRNA abundance, and prostate cancer risk is in-
versely correlated with its expression (13, 14). In addition, 
rs13385191 is associated with nonfatal outcome of prostate 
cancer (9, 12). Linkage of the LDAH locus with prostate 
cancer suggests that loss of the lipid droplet-associated hydro-
lase (LDAH) function has a role in prostate tumorigenesis.
The single polypeptide encoded by LDAH is predicted to 
be a serine hydrolase of the /-fold type (15, 16). Homo-
logs in multiple species, including yeast (YPR147C), suggest 
a conserved function at LDs; however, LDAH’s molecular 
function remains uncertain but has recently been investi-
gated. Goo et al. reported that LDAH is a CE hydrolase 
(17). This finding is intriguing inasmuch as recent studies 
have linked accumulation of CEs in LDs to prostate and 
breast cancer aggressiveness (18, 19). Supporting a func-
tion in CE metabolism, two other SNPs in LDAH are associ-
ated with changes in LDL cholesterol (20, 21). However, 
LDAH is near APOB on chromosome 2, and these SNPs 
were originally linked to APOB, a confounding factor be-
cause APOB is involved in cholesterol metabolism.
Besides LDAH, other lipases have been implicated in CE 
hydrolysis. NCEH1 has been reported to hydrolyze CEs 
(22), but at least in mice, it has also been reported to hy-
drolyze ether lipid 2-acetyl monoalkylglycerol (23). The LD-
localized hormone-sensitive lipase (HSL) contributes to CE 
hydrolysis (23–25). Whether HSL has a major role in CE 
hydrolysis in macrophages is debated because CE hydroly-
sis still occurs in its absence (26). Lysosomal acid lipase also 
contributes to cellular CE metabolism and regulates mac-
rophage cholesterol efflux, potentially through lipophagy 
(27–29), but whether it has access to LDs under normal 
conditions is not clear. Thus, the enzymes that hydrolyze 
CEs at LDs are uncertain.
In this study, we tested the reported role for LDAH in CE 
hydrolysis and the metabolism of other neutral lipids by 
generating and analyzing a knockout mouse model lacking 
this enzyme.
MATERIALS AND METHODS
Amino acid sequence analysis
CG9186 (dLDAH) secondary structure was predicted with JPred4 
(30) and PSIPRED (31, 32).
Cell culture and transfection
HeLa cells were cultured in DMEM with 10% FBS and Pen-
Strep. S2 cell culture was performed as described (33). HeLa and 
S2 cells were transfected using FuGENE HD (Promega, Madison, 
WI) and Effectene (Qiagen, Germantown, MD) transfection re-
agents, respectively, according to the manufacturer’s instructions. 
LDs were induced and stained as described (33–35), S2 cells were 
induced with 1 mM oleic acid-BSA, and HeLa cells were induced 
with 0.5 mM oleic acid coupled to BSA. For colocalization experi-
ments, a C-terminally tagged ADRP-YFP fusion construct or 
dsRed2-ER (Clontech, Mountain View, CA) was cotransfected 
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1.5.1.2, and statistical analyses were performed with the Per-
seus software (Max Planck Institute of Biochemistry, Munich, 
Germany (41)).
Lipid hydrolase activity assays
Mouse tissues were homogenized in buffer A (0.25 M sucrose, 
1 mM EDTA, 1 mM DTT, 20 g/ml leupeptine, 2 g/ml anti-
pain, 1 g/ml pepstatin) followed by centrifugation at 20,000 g 
for 30 min at 4°C. The protein content of the 20,000 g infranatant 
was then determined by the Bio-Rad Protein Assay Kit with BSA as 
a standard.
Measurement of in vitro triacylglycerol (TG) hydrolase activity 
was as described (42). Briefly, 10 g of WAT protein or 100 g of 
liver protein in a total volume of 100 l buffer A were incubated 
with 100 l of a phospholipid-emulsified triolein substrate solu-
tion. The substrate for the measurement of TG-hydrolytic activity 
in WAT contained 1.67 mM triolein, 190 M phosphatidylcho-
line/phosphatidylinositol (ratio 3:1), and 10 Ci/ml 3H-triolein 
and was prepared by sonication in 100 mM potassium phosphate 
buffer, pH 7.0 with 2% fatty acid-free BSA. For measurement of 
TG hydrolase activity in the liver, the substrate solution consisted 
of 0.32 mM triolein, 45 M phosphatidylcholine/phosphati-
dylinositol (ratio 3/1), and 10 Ci/ml [9,10-3H] triolein and was 
prepared as described above. After 1 h at 37°C, released free fatty 
acids (FFAs) were extracted and quantified by liquid scintillation 
counting.
The measurement of in vitro CE hydrolase activities in WAT 
and liver was performed according to the measurement of TG-
hydrolase activity using a phospholipid-emulsified cholesteryl ole-
ate substrate solution, which consisted of 0.45 mM cholesteryl 
oleate, 0.45 mM PC/PI (ratio 3:1), and 1 Ci / ml 14C-cholesteryl 
oleate.
To measure hydrolase activity of LDAH protein in vitro, we 
used lysates of cells overexpressing LDAH or CG9186 for the lipid 
hydrolase activity assays.
Western blots
Tissues were lyzed in RIPA buffer with a dounce homogenizer 
and sonicated. For Western blot analysis, 50 µg protein of lysates 
were loaded. LDAH was detected using a polyclonal antibody di-
rected against the C terminus of murine LDAH at a dilution 1:500 
(17). The tubulin antibody was purchased from Sigma-Aldrich 
(Cat. no. T5168) and used at a dilution of 1:2000.
qRT-PCR analysis
The following primers were used in qRT-PCR analysis. Expres-
sion was normalized to the average of -actin and cyclophilin 
levels.
mLDAH: 5′-CTTCACGTGATGAAGCGAGT-3′ (forward primer), 
5′-AGTTGGGAAGAGCAGAAAGG-3′ (reverse primer); mHSL: 
5′-ACGAGACAGGCCTCAGTGTGA-3′ (forward primer), 5′-CCAC G-
CAACTCTGGGTCTATG-3′ (reverse primer); mATGL: 5′-GAGCCCC-
GGGGTGGAACAAGAT-3′ (forward primer), 5′-AAAAGGTGGT-
GGGCAGGAGTAAGG-3′ (reverse primer); m-Actin: 5′-CATCGT-
GGGCCGCTCTA-3′ (forward primer), 5′-CAC CCACATAGGAGTC-
CTTCTG-3′ (reverse primer); mCyclophilin: 5′-TGGAAGAGCA-
CCAAGACAACA-3′ (forward primer), 5′-TGCCGGAGTCGA-
CAATGAT-3′ (reverse primer).
Statistics
Statistical significance was tested using Student t-test. For ex-
periments with multiple time points, a two-way ANOVA was used 
(GraphPad Prism Software).
Value less than 0.05 would have been considered significant in 
all statistical analyses.
Isolation of bone marrow-derived macrophages
Femurs and tibia were dissected, and muscle was removed. 
Bone marrow was flushed with 5 ml of DMEM/F12 (Thermo Fisher 
Scientific, Waltham, MA) with a 5 ml syringe and a 25 gauge nee-
dle. Cells were centrifuge at 500 rpm for 10 min, resuspended in 
medium (DMEM/F12 + 20% HI-FBS + 20% L929 conditioned 
medium), and plated on petri dishes. On day 4, fresh medium was 
added to the plates. Experiments were performed on day 7.
Cholesterol ester quantification and turnover 
measurement
Cells were seeded in 6-well plates, and medium was changed to 
contain 1% FBS and loaded with 50 µg/ml of acetylated low-den-
sity lipoproteins (acLDLs) (Alfa Aesar, Ward Hill, MA) for 18 h. 
For quantification of total CEs, lipids were extracted. Cells were 
washed in PBS, and 750 µl of hexane:isopropanol (2:3) were 
added to each well and incubated rocking for 10 min at room 
temperature. The organic solvent phase was collected and dried. 
Lipids were resuspended in 40 µl of chloroform, spotted on a TLC 
plate, and developed in hexanes:ethylether:acetic acid (80:20:1). 
Cholesterol esters were quantified by charring with CuSO4 and 
densitometry. Values were normalized to protein content deter-
mined by BCA assay.
To measure cholesterol ester turnover, cells were loaded 
with 50 µg/ml acLDL for 12 h and subsequently labeled with 0.25 
µCi/ml 14C-oleate (Perkin-Elmer, Waltham, MA) for 6 h. The me-
dium was changed, and 10 µg/ml Sandoz 58-035 ACAT inhibitor and 
2 µg/ml methyl--cyclodextrin (both from Sigma Aldrich, St. 
Louis, MO) were added. Lipids were extracted after 0, 8, and 24 h 
and separated by TLC as described above. The CE band was 
scraped and quantified by scintillation counting.
Metabolite and hormone measurements
Blood glucose levels were measured using a FreeStyle Lite glu-
cosemeter (Abbott Diabetes Care, Alameda, CA). Serum leptin 
levels and liver glycogen levels were determined by the Yale Mouse 
Metabolic Phenotyping Center Analytical Core. Testosterone and 
corticosterone assays were performed by the Vanderbilt Univer-
sity Medical Center Hormone Assay and Analytical Services Core.
Lipidomics
Lipidomics analysis of white adipose tissue (WAT), brown adi-
pose tissue (BAT), and liver of 4-week ad libitum-fed animals fed 
a high-fat diet (HFD) was performed as described (39). For liquid 
chromatography-mass spectrometer analysis of lipids from livers 
of 22-week HFD ad libitum-fed animals, lipids were extracted 
from liver corresponding to 75 g of protein by chloroform/
methanol extraction (38). Detected lipids were identified using 
LipidSearch (MKI, Tokyo, Japan). Peaks were defined through 
raw files, product ion, and precursor ion accurate masses. Lipid 
species were identified by database (>1,000,000 entries) search of 
positive and negative ion adducts. The accurate mass-extracted 
ion chromatograms were integrated for each identified lipid spe-
cies and peak areas obtained for quantitation. An internal stan-
dard for phosphatidylinositol (PI 17:0–20:4; Avanti Polar Lipids, 
Alabaster, AL), which spiked prior to extraction, was used for 
normalization.
Proteomics
WATs and livers from wild-type and Ldah knockout mice were 
collected and processed by filter-aided sample preparation as de-
scribed (40). Eluted peptides were analyzed by HPLC (EASY-nLC 
1000, Thermo Scientific), combined with an Orbitrap mass spec-
trometer (Q Exactive HF, Thermo Scientific). Raw mass spec-
trometry data were processed by the MaxQuant software version 
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LDAH knockout mouse model 229
confocal microscopy. mCherry-tagged LDAH colocalized 
with the LD marker ADRP in oleate-loaded HeLa cells (Fig. 
1B). In the absence of LDs, LDAH localized to the endo-
plasmic reticulum (ER) (Fig. 1C).
Many LD proteins bind to LDs via a hydrophobic, mem-
brane-embedded sequence (class I binding proteins) or 
an amphipathic helix (class II binding proteins) (46, 47). 
dLDAH contains a short hydrophobic motif (amino ac-
ids 152–201), predicted to be mostly -helical but contain-
ing prolines (Fig. 1D), conserved among species, suggesting 
a hydrophobic hairpin, class I LD-binding motif. To examine 
this, we expressed a fusion construct of amino acids 152–
201 with an N-terminal mCherry-tag in S2 cells. This protein 
localized to LDs in cells treated with oleic acid (Fig. 1E). In 
contrast, dLDAH in which amino acids 157–200 were 
RESULTS
LDAH/C2Orf43 orthologs localize to lipid droplets via a 
hydrophobic domain
In Drosophila S2 cells and Saccharomyces cerevisiae, LDAH 
homologs copurify with LD proteins (43, 44). Drosophila 
CG9186 (referred to as dLDAH hereinafter) was highly en-
riched in the top fraction of a sucrose gradient used to 
separate cellular proteins, a purification profile typical of 
bona fide LD proteins, such as HSL (Fig. 1A). Consistent 
with this result, Drosophila and human LDAH localize to 
LDs (17, 45).
To confirm the cellular localization of human LDAH, 
also known as C2ORF43 (17), we expressed the protein fused 
to an mCherry or GFP-tag and examined its localization by 
Fig. 1. LDAH homologs localize to LDs with a hy-
drophobic hairpin. A: The Drosophila homolog of 
LDAH has the purification profile of a LD protein. 
Normalized purification factors of different organelle 
markers across a cellular fractionation are plotted. 
HSL is the LD marker; protein disulfide isomerase is 
the ER marker; alcohol dehydrogenase is the cytosolic 
marker; lamin is the nuclear marker. B, C: LDAH local-
izes to LDs or to the ER in the absence of LDs. B: 
mCherry-tagged LDAH colocalizes with ADRP in HeLa 
cells in the presence of LDs. Cells were transfected 
with constructs and treated with 0.5 mM oleic acid 
overnight. Representative images are shown. Scale bar, 
10 m. C: GFP-tagged LDAH localized to the ER in the 
absence of LDs. Cells were transfected with constructs 
and imaged the next day. Representative images are 
shown. Scale bar, 10 m. D, E: A hydrophobic hairpin 
motif localizes LDAH to LDs. D: A hydrophobic seg-
ment comprising amino acids 160–195 of Drosophila 
CG9186/LDAH is predicted to have a hairpin struc-
ture and is responsible for LD binding. The /-
hydrolase fold and the catalytic GxSxG-motif are 
indicated. -Helices predicted by PSIPRED and JPred 
4 are shown in pink. E: Full-length mCherry-tagged 
dLDAH and amino acids 152–201 of dLDAH localize 
to LDs after oleic acid treatment, while deletion of 
amino acids 157–200 results in ablation of LD binding. 
GFP-Sec61 was used to visualize the ER. Cells were 
transfected with constructs and treated with 1 mM 
oleic acid overnight. LDs were stained with AUTOdot 
(blue). Representative images are shown. Scale bar, 
5 m. F: LDAH overexpression does not affect choles-
terol esterase, retinol esterase, or triacylglycerol hydro-
lysis activity. Nanomoles of free fatty acids (FFA) per 
(hour per milligram protein) ± SD. Values are means 
(n = 4). Activities were determined in lysates of WT 
HeLa or S2 cells and cells overexpressing the LDAH 
homologs using phospholipid-emulsified 3H-labeled 
lipids at neutral pH. S2 cells overexpressing HSL were 
used as a positive control. ALDH, alcohol dehydroge-
nase; PDI, protein disulfide isomerase
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bone marrow–derived macrophages (BMDM) of Ldah 
knockout mice (Fig. 2C, D, supplemental Fig. S1A). To 
further confirm the absence of the LDAH protein in 
knockout mice, we performed mass-spectrometry analy-
sis of lysates from WAT and livers of wild-type and Ldah 
knockout mice. No LDAH peptides were detected in tis-
sues of knockout mice, whereas five different, unique 
peptides covering different parts of the protein were 
detected in the wild-type samples (Fig. 2E). In contrast, 
the abundance of peptides derived from the TG lipase 
adipose triglyceride lipase (ATGL) were found at simi-
lar levels in each genotype. Consistent with these obser-
vations, we found that LDAH deletion did not result in 
a compensatory up-regulation of the major neutral lipid 
lipases ATGL or HSL, as determined by qPCR (supple-
mental Fig. S1B, C).
Ldah knockout animals were born at the expected Men-
delian ratio (data not shown) and displayed no gross phe-
notypic changes or alterations in tissue morphology at 8–12 
weeks of age (Fig. 3, supplemental Fig. S2). The size of adi-
pocytes and amount of oil red O-staining of livers and adre-
nal glands were similar in Ldah wild-type and knockout 
animals (Fig. 3A, B, supplemental Fig. S2).
Loss of LDAH does not affect body mass, body 
composition, glucose tolerance, or tissue lipid 
composition
To analyze and challenge the metabolism of Ldah knock-
out animals, we placed male mice on rodent chow or 
replaced by a generic linker sequence (N-AAAGGGGSGGG-
GS-C) did not target LDs.
Since LDs store neutral lipids, such as CE, TG, and reti-
nol esters, we measured hydrolase activity toward these sub-
strates in lysates from cells overexpressing LDAH versus 
control cells (Fig. 1F). Consistent with a previous report 
(45), overexpression of mammalian or Drosophila LDAH 
did not increase hydrolase activity, whereas overexpression 
of HSL increased CE and TG hydrolysis activities
LDAH protein is absent in mice with a targeted gene-
disruption allele
To investigate the physiological function of LDAH/
C2ORF43, we generated an Ldah knockout mouse and 
evaluated it for metabolic phenotypes. Sequencing of the 
genomic locus of these animals confirmed replacement of 
a region from exon 2, downstream of the start codon, to 
base 169 of exon 3, including the predicted catalytic Gx-
SxG motif (schematic shown in Fig. 2A), with a LacZ-Neo-
mycin targeting cassette. Ldah mRNA was absent in tissues 
of Ldah knockout mice and 50% reduced in Ldah hetero-
zygous mice (Fig. 2B).
Western blot analysis with an antibody binding an 
LDAH C-terminal antigen showed that the LDAH pro-
tein was present in many tissues of wild-type animals, 
including prostate, with highest levels found in WAT 
(Fig. 2D, supplemental Fig. S1A). In contrast, LDAH 
protein was undetectable in liver, BAT and WAT, adre-
nal gland, prostate, brain, spleen, kidney, testis, and 
Fig. 2. LDAH is absent in mice with a targeted gene-
disruption allele. A: A gene knockout cassette disrupts 
exons 2 and 3 of the Ldah gene. B–E: Ldah mRNA and 
protein are absent in Ldah KO animals. Schematic of 
the Ldah gene locus and targeting cassette (Knockout 
Mouse Project). Genotype of animals was confirmed 
with SD30636, NeoF, and SD primers. B: Ldah mRNA is 
reduced to 50% of the gene product in heterozygous 
mice and absent in Ldah KO animals. Relative Ldah 
mRNA abundance ± SD in different tissues of Ldah WT 
(black bars), heterozygous (gray bars), and KO mice 
(white bars) determined by qPCR. Ldah values were 
normalized to the average of -actin and cyclophilin. 
Values are means (n = 3–4). C: Western blots against 
LDAH in liver tissue from male and female Ldah WT 
and KO animals confirmed loss of LDAH protein. Tu-
bulin was used as a loading control. D: LDAH protein 
is undetectable in tissues of male Ldah KO animals by 
Western blot. Low and high exposures are shown for 
tubulin. E: Mass spectrometry (MS) analysis confirmed 
absence of LDAH in Ldah KO animals. Peptides that 
were identified by MS for LDAH (top) or ATGL (bot-
tom) in WT or Ldah KO animals are mapped to the 
protein sequence. For ATGL, peptides were identified 
in both WT and KO tissue across the length of the pro-
tein. For LDAH, no peptides were identified in KO 
animals, and peptides from various parts of the pro-
tein were detected in lysates from WT tissue. Data 
from WAT and livers of two animals per genotype were 
combined for the graph.
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as determined by oral glucose tolerance test, was also not 
affected on chow or HFD (Fig. 4C).
We assayed for a role of LDAH in lipid metabolism, but 
found no changes between genotypes on a HFD in serum 
lipids or levels of major lipid species in liver, WAT or BAT 
(Table 1, supplemental Fig. S5A, B). Neither did we detect 
differences in the accumulation of neutral lipids in the livers 
of Ldah knockout and control mice on chow or HFD as deter-
mined by oil red O staining (Fig. 3B). Major metabolic param-
eters and lipid classes were not changed in Ldah knockout 
mice on HFD (Fig. 3, supplemental Figs. S3–S5).
Because phenotypes related to lipid metabolism were 
not observed on chow diet or with short-term HFD, we fur-
ther challenged the metabolism of the Ldah knockout mice 
by feeding them a 60% HFD for 22 weeks. Despite the lon-
ger dietary challenge, body weight gain was not affected by 
LDAH loss (Fig. 4D). Neither was the percentage of body 
fat (Fig. 4E), fasted serum glucose, leptin, TG, or ketone 
bodies (Table 1). There were no apparent changes in total 
TG, CEs, or other major lipid species as determined by thin 
layer chromatography and lipidomics (Fig. 4F, G). Liver 
glycogen content was comparable between genotypes (sup-
plemental Fig. S5C). The histology of liver, WAT and BAT, 
and heart tissues were not affected in Ldah knockout mice 
after 22 weeks on HFD (Fig. 3B, supplemental Fig. S2).
In an overnight fasting experiment, with subsequent 
cold exposure without access to food, knockout animals 
tolerated this stress slightly better than wild-type animals 
by maintaining their body temperature in the cold. How-
ever, the differences were minor and only significant at 
some time points, and overall both genotypes maintained 
blood glucose levels and body weight (supplemental 
Fig. S6).
lard-based 60% kcal% fat-containing diet. While all mice 
gained body weight more rapidly when fed a high-fat diet 
(HFD), knockout mice gained weight at a rate similar to 
their wild-type littermates (Fig. 4A). After 4 weeks on an 
HFD, we evaluated their energy metabolism. There were no 
differences in body composition (Fig. 4B), energy expendi-
ture, locomotor activity, water or food intake, respiratory 
exchange ratio, oxygen consumption, or carbon dioxide pro-
duction (supplemental Figs. S3, S4). Glucose homeostasis, 
Fig. 3. Histological analysis revealed no abnormalities in Ldah 
KO animals. A, B: Histology of tissues from animals fed a chow diet 
(A) or a HFD (B). A: Oil red O staining of liver and adrenal glands, 
and hematoxylin and eosin (H and E) staining of white adipose 
tissue (WAT) from 10- to 12-week-old Ldah wild-type or knockout 
animals fed a chow diet. B: Oil red O staining of livers after 4-week 
HFD feeding (top panel), and H and E staining of livers and WAT 
after 22 weeks on a HFD (bottom panels). Tissues are shown at a 
magnification of ×10.
Fig. 4. Loss of LDAH does not affect body mass gain, 
body composition, glucose tolerance, or tissue lipid 
composition. Loss of LDAH does not affect body mass 
gain, glucose tolerance, or body composition on chow 
or HFD. A: Ldah KO mice gain body mass as WT ani-
mals on chow or HFD. Body mass (g) ± SD of Ldah WT 
(closed squares) and KO (open squares) animals on 
chow (black squares) or 4-week HFD (red squares). 
Values are means (n = 6–8). B: Body composition (g or 
%) ± SEM of Ldah WT (closed bars) and KO (open 
bars) animals on chow (black bars) or 4-week HFD 
(red bars). Values are means (n = 6–8). C: Blood glu-
cose (mg/dl) ± SEM of Ldah WT (closed squares) and 
KO (open squares) animals on chow (black squares) 
or 4-week HFD (red squares) after oral glucose toler-
ance test. Values are means (n = 6–8). D: Body mass (g) 
± SD of Ldah WT (black squares) and KO (gray 
squares) animals on 22-week HFD. Values are means 
(n = 6–9). E: Body composition (g or %) ± SEM of 
Ldah WT (black bars) and KO (gray bars) animals on 
22-week HFD. Values are means (n = 6–9). F, G: Lipid 
composition of livers after 22 weeks on HFD is not af-
fected by loss of LDAH. F: CEs and TGs in liver lysates 
separated by TLC and stained by cerium molybdate as 
described [Krahmer et al., 2011 (34)]. G: Fold-change 
of lipid classes ± SD in Ldah KO versus WT animals 
determined by MS. Values are means (n = 4).
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DISCUSSION
We show here that the LD-localized putative lipase LDAH 
does not have a major, physiologically detectable role in 
murine CE metabolism. These findings contrast with previ-
ous in vitro studies that reported LDAH functions as a CE 
hydrolase (17). In our animal studies, LDAH deletion did 
not change CE levels, CE hydrolysis activity, or the metabolism 
of TGs or other major lipid classes. Moreover, we found no 
evidence for CE hydrolysis activity in in vitro assays of lysates 
with the overexpressed enzyme. We also found no evidence 
for a role of LDAH in whole-body energy metabolism.
Because we found no changes in CE metabolism in 
LDAH-deficient mice, it is unlikely that LDAH has CE hy-
drolysis activity and any role in macrophage cholesterol ef-
flux. The previous report (17) had limitations. For example, 
the CE hydrolysis activity reported was minimal in compari-
son with the activity of the known CE hydrolase HSL, and 
the differences shown for overexpression of LDAH in com-
parison with a catalytically dead enzyme were negligible. 
Our results are consistent with another study that detected 
Loss of LDAH does not affect cholesterol ester turnover 
or hydrolysis
Since LDAH had been implicated in CE hydrolysis and 
efflux from macrophages (17), we assayed CE metabolism 
in Ldah knockout mice. We isolated macrophages from 
bone marrow of wild-type and knockout mice and tested 
CE accumulation and turnover after acetylated LDL (acLDL) 
treatment. After overnight incubation with 50 µg/ml acLDL, 
Ldah wild-type and knockout cells had similar amounts 
of LDs and CEs (Fig. 5A–C). Using radioactive oleic acid 
to label lipids, we determined the turnover of CEs with 
ACAT1 inhibitor and -cyclodextrin as a cholesterol accep-
tor in the medium and found no differences in macro-
phages lacking LDAH (Fig. 5D). Consistent with these 
results, we observed no changes in CE hydrolysis activity 
in WAT or liver lysates from Ldah knockout animals (Fig. 
5E, F). TG hydrolysis activity was also similar (supplemental 
Fig. S7). Corticosterone and testosterone levels were simi-
lar in wild-type and knockout mice, suggesting it is unlikely 
that LDAH affects murine steroid hormone metabolism 
(Table 1).
TABLE 1. Serum parameters of Ldah WT and KO mice
WT (n) KO (n) P 
Corticosterone (ng/ml) 97.26 ± 75.65 114.02 ± 80.13 0.35
 (6)  (8)
Testosterone (ng/ml) 2.03 ± 1.97 1.1 ± 1.34 0.18
 (7)  (6) Chow diet, ad lib
Cholesterol (mg/dl) 132.62 ± 30.05 137.87 ± 8.21 0.34
 (6)  (6)
HDL (mg/dl) 97.85 ± 21.02 99.91 ± 5.04 0.41
 (6)  (6)
LDL (mg/dl) 17.36 ± 3.17 17.62 ± 2.04 0.43
 (6)  (6)
TG (mg/dl) 52.45 ± 25.24 64.34 ± 30.58 0.24
 (6)  (6)
NEFA (mmol/L) 0.92 ± 0.23 0.99 ± 0.21 0.29
 (6)  (6)
B-Hb (mmol/L) 0.18 ± 0.06 0.14 ± 0.03 0.08
 (6)  (6) 4 weeks 60% high-fat diet, ad lib
TG (mg/dl) 84.02 ± 7.97 75.09 ± 9.21 0.11
 (3)  (4)
B-Hb (mmol/L) 0.51 ± 0.17 0.49 ± 0.11 0.44
 (3)  (4)
Glucose (mg/dl) 166.00 ± 12.31 171.88 ± 20.25 0.26
 (6)  (9)
Leptin (ng/ml) 44.19 ± 7.29 44.54 ± 6.02 0.45
 (6)  (9) 21 weeks 60% high-fat diet, fasted
Cholesterol (mg/dl) 68.49 ± 8.14 67.46 ± 3.78 0.38
 (6)  (7)
HDL (mg/dl) 51.60 ± 3.86 51.20 ± 4.36 0.43
 (6)  (7)
LDL (mg/dl) 5.50 ± 0.80 5.73 ± 0.31 0.25
 (6)  (7)
TG (mg/dl) 65.38 ± 9.05 62.01 ± 10.84 0.28
 (6)  (7)
NEFA (mmol/L) 1.93 ± 0.28 1.81 ± 0.41 0.28
 (6)  (7)
B-Hb (mmol/L) 1.96 ± 0.41 2.19 ± 0.58 0.22
 (6)  (7) Fasted, cold-exposed
Serum parameters measured in different experiments for WT and Ldah KO animals are reported. The 
number of animals of a certain genotype (n) used for each study is shown in parentheses. Measurements 
belonging to one experiment are grouped together, with different experiments being separated by double rules. 
The feeding state and, where applicable, additional treatments of animals in a given experiment are indicated in 
the last column. Student’s t-test was performed for statistical analysis. B-Hb, -hydroxybutyrate; NEFA, 
nonesterified fatty acid.
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is associated with increased prostate cancer aggressiveness 
(6, 18). An intriguing possibility is that cancer develop-
ment could be linked to changes in LDAH enzymatic activ-
ity. Lower expression of LDAH in the prostate itself due to 
a sequence variation could result in remodeling of lipid 
metabolism to promote cancer growth. However, we did 
not find a role for LDAH in lipid metabolism or in prostate 
cancer development, because we have found no signs of 
prostate neoplasia or cancer in the knockout mice, albeit 
we analyzed only a small number of animals at 1 year of age 
(data not shown). One confounding factor in interpreting 
the human genetic studies and a potential connection among 
LDAH, lipid metabolism, and cancer is the proximity of 
the LDAH and APOB loci. The modest linkage disequilib-
rium found between the LDAH SNP with SNPs near APOB 
makes the effect of genetic variants of LDAH on lipid me-
tabolism and cancer risk difficult to dissect from those 
which might be driven by apoB. SNPs can also exert regu-
latory effects over hundreds of kilobases (48). Thus, the 
LDAH SNP (or linked polymorphisms close by) could have 
an effect on APOB expression, which in turn might be re-
sponsible for the genetic associations observed for this locus.
The expression pattern of LDAH in humans suggests an 
additional link to prostate cancer. Although LDAH levels 
appear to be high in WAT in mice, LDAH levels are high in 
adrenal glands in humans (http://www.humanproteome-
map.org; www.proteomicsdb.org; www.gtexportal.org), the 
primary production site of steroid hormones such as an-
drogens from cholesterol (49). Many prostate cancer cells 
depend on androgenic signals from the adrenal gland (50, 
51), and therefore, LDAH might affect risk for prostate 
cancer by affecting androgenic metabolism in adrenal 
gland LDs.
no activity toward any major lipid species, including CEs in 
in vitro assays (45). However, at present, it remains possible 
that under specific physiological or pathological condi-
tions, LDAH might play a role in CE or TG hydrolysis, or 
both, in macrophages. We also cannot exclude possible re-
dundancy of LDAH activity with other murine cholesterol 
esterases, which might compensate for LDAH loss in vivo.
LDAH will need to be tested for alternative activities. We 
ruled out lipase activity toward major species of CEs, TGs, 
and other lipid classes. However, LDAH might hydrolyze a 
structurally similar, potentially lowly abundant or difficult-
to-detect molecule, such as a modified sterol ester, oxys-
terol ester, or ether lipid. We found no differences in total 
sterols or oxysterols in WAT or liver from LDAH knockout 
mice and no activity toward ether TG in overexpression ex-
periments (data not shown). Our efforts to reveal the sub-
strate of LDAH by untargeted mass spectrometry-based 
lipidomics have been, thus far, unsuccessful.
LDAH homologs localize to LDs via a hydrophobic hair-
pin targeting motif, in agreement with previous reports 
(45). Accordingly, LDAH is a class I LD protein (i.e., target-
ing LDs from the ER). The hydrophobicity of LDAHs’ LD 
targeting motif and low propensity to be displaced from 
shrinking LDs during lipolysis (35) suggest that LDAH 
evolved for optimal substrate access to the hydrophobic LD 
core. However, whether LDAH has an enzymatic function 
on LDs is not known.
With no known function, the mechanism linking LDAH 
to human disease remains enigmatic. A SNP in the LDAH 
gene associated with reduced mRNA expression is also as-
sociated with an increased risk for prostate cancer (9, 10, 
13, 14). Prostate cancer is one of the cancer types known to 
upregulate lipid metabolism, and CE accumulation in LDs 
Fig. 5. Loss of LDAH does not affect cholesterol es-
ter (CE) turnover or hydrolysis. CE storage in bone 
marrow-derived macrophages was not affected by 
LDAH loss. Cells were treated with 50 µg/ml AcLDL 
for 18 h before imaging or lipid extraction. A: Repre-
sentative images are shown. LDs were stained with 
BODIPY. Scale bar, 10 m. B: LD area per cell (µm2). 
Values are means, and individual data points are plot-
ted (n > 30). C: CEs per protein determined by thin-
layer chromatography. D: LDAH does not play a role 
in cholesterol ester turnover in bone marrow-derived 
macrophages. Percentage CEs ± SD remaining. Values 
are means (n = 3). E, F: LDAH deficiency does not af-
fect cholesterol esterase activity. CE hydrolase activity 
in white adipose tissue (WAT) and liver of Ldah WT 
(black bars) and KO mice (white bars). Activities were 
determined in the 20,000 g infranatant using phos-
pholipid-emulsified 14C-labeled cholesterol oleate at 
neutral pH. E: Nanomoles of free fatty acids (FFA) per 
(hours per milligram protein) ± SD in WAT of Ldah 
WT (black bars) or KO mice (white bars). Values are 
means (n = 5). F: Nanomoles of FFA per (hours per 
milligrams protein) ± SD in livers of Ldah WT (black 
bars) or KO mice (white bars). Values are means 
(n = 7–8). CEH, cholesterol ester hydrolase.
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In summary, our data suggest that SNPs in LDAH affect 
prostate cancer risk through a mechanism other than CE 
hydrolysis activity and that LDAH has an alternative LD- 
associated metabolic function. Whether LDAH functions 
in the metabolism of lipids, other metabolites, or perhaps 
xenobiotics remains to be elucidated.
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